Theratechnologies Inc
THTX3.170USD
+0.010+0.31%
取引時間 （ET）15分遅れの株価
145.75M時価総額
損失額直近12ヶ月PER
詳細情報 Theratechnologies Inc 企業名
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
企業情報
企業コードTHTX
会社名Theratechnologies Inc
上場日Dec 21, 1993
最高経営責任者「CEO」Mr. Paul Levesque
従業員数94
証券種類Ordinary Share
決算期末Dec 21
本社所在地2015 Peel Street, 11th Floor
都市MONTREAL
証券取引所NASDAQ Capital Market Consolidated
国Canada
郵便番号H3A 1T8
電話番号15143367800
ウェブサイトhttps://www.theratech.com/
企業コードTHTX
上場日Dec 21, 1993
最高経営責任者「CEO」Mr. Paul Levesque
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Thomas Molson
Mr. Andrew Thomas Molson
Independent Director
Independent Director
137.50K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Independent Director
Independent Director
110.90K
--
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
72.80K
--
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
59.75K
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
51.25K
--
Ms. Dale Maccandlish Weil
Ms. Dale Maccandlish Weil
Independent Director
Independent Director
44.16K
--
Mr. Philippe Dubuc
Mr. Philippe Dubuc
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
15.75K
--
Dr. Christian Marsolais, Ph.D.
Dr. Christian Marsolais, Ph.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
14.82K
--
Mr. Jocelyn Lafond
Mr. Jocelyn Lafond
General Counsel, Company Secretary
General Counsel, Company Secretary
4.50K
--
Mr. Joseph P. Arena
Mr. Joseph P. Arena
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Thomas Molson
Mr. Andrew Thomas Molson
Independent Director
Independent Director
137.50K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Independent Director
Independent Director
110.90K
--
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
72.80K
--
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
59.75K
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
51.25K
--
Ms. Dale Maccandlish Weil
Ms. Dale Maccandlish Weil
Independent Director
Independent Director
44.16K
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
EGRIFTA
13.88M
72.87%
Trogarzo
5.17M
27.13%
地域別USD
会社名
収益
比率
United States
19.05M
100.00%
Europe
0.00
0.00%
事業別
地域別
事業別USD
会社名
収益
比率
EGRIFTA
13.88M
72.87%
Trogarzo
5.17M
27.13%
株主
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
株主統計
種類
株主統計
株主統計
比率
Investissement Québec
19.83%
Soleus Capital Management, L.P.
10.44%
Nantahala Capital Management, LLC
5.27%
Morgan Stanley & Co. LLC
4.82%
AIGH Capital Management, LLC.
3.37%
Other
56.27%
株主統計
株主統計
比率
Investissement Québec
19.83%
Soleus Capital Management, L.P.
10.44%
Nantahala Capital Management, LLC
5.27%
Morgan Stanley & Co. LLC
4.82%
AIGH Capital Management, LLC.
3.37%
Other
56.27%
種類
株主統計
比率
Private Equity
23.20%
Hedge Fund
15.71%
Research Firm
5.11%
Investment Advisor/Hedge Fund
1.73%
Individual Investor
1.15%
Investment Advisor
1.14%
Bank and Trust
0.43%
Venture Capital
0.03%
Other
51.49%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
90
22.35M
48.61%
-1.02M
2025Q1
91
22.45M
48.83%
-1.34M
2024Q4
86
23.57M
51.25%
-895.81K
2024Q3
83
24.25M
52.74%
-40.47K
2024Q2
85
24.07M
52.35%
-127.35K
2024Q1
90
23.97M
52.12%
-218.82K
2023Q4
90
24.01M
52.22%
+1.91M
2023Q3
92
7.44M
30.84%
-1.19M
2023Q2
93
7.55M
31.28%
-1.05M
2023Q1
94
7.50M
31.54%
-1.18M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Investissement Québec
9.12M
19.83%
--
--
Apr 29, 2025
Soleus Capital Management, L.P.
4.80M
10.44%
-1.00
-0.00%
Apr 29, 2025
Nantahala Capital Management, LLC
2.42M
5.27%
-259.67K
-9.68%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.21M
4.82%
-59.37K
-2.61%
Mar 31, 2025
AIGH Capital Management, LLC.
1.75M
3.81%
-536.91K
-23.48%
Mar 31, 2025
Worth Venture Partners, LLC
576.93K
1.25%
-163.09K
-22.04%
Mar 31, 2025
National Bank of Canada
197.07K
0.43%
+4.94K
+2.57%
Mar 31, 2025
Molson (Andrew Thomas)
137.50K
0.3%
--
--
Apr 29, 2025
Svoronos (Dawn A)
110.90K
0.24%
--
--
Apr 29, 2025
Harbour Investments, Inc
96.11K
0.21%
+8.33K
+9.49%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
DFA Dimensional International Core Equity 2 ETF
0%
DFA Dimensional International Core Equity 2 ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
日付
種類
比率
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
Jul 20, 2023
Merger
4<1
